CHST2 Antibody

What is CHST2 and what cellular functions does it regulate?

Carbohydrate Sulfotransferase 2 (CHST2), also known as N-acetylglucosamine-6-O-sulfotransferase 1 (GlcNAc6ST-1) and Gal/GalNAc/GlcNAc 6-O-sulfotransferase (GST-2), is a Golgi-localized type II membrane protein that transfers sulfate onto the 6-O or 4-O positions of GalNAc, Gal, and GlcNAc residues on glycoproteins, proteoglycans, and glycolipids . This enzyme is critically involved in the biosynthesis of L-selectin ligand sialyl 6-sulfo Lewis X and plays a significant role in lymphocyte homing processes . Recent research has also demonstrated CHST2's involvement in cancer progression, particularly in breast cancer cell migration and metastasis through regulation of MECA79 antigen synthesis .

What are the recommended applications for CHST2 antibodies in research?

CHST2 antibodies have been validated for multiple research applications including Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), and immunocytochemistry/immunofluorescence (ICC/IF) . For Western blot applications, most antibodies can be used at dilutions ranging from 1:500 to 1:3000, while ICC/IF applications typically require dilutions between 1:100 and 1:1000 . ELISA applications may require higher dilutions, with some antibodies recommended at 1:10000 . It is essential to optimize antibody dilutions for each specific application and experimental system to achieve optimal results and signal-to-noise ratios .

How can I validate the specificity of CHST2 antibodies in my cellular system?

Validating antibody specificity is crucial for ensuring reliable research results. For CHST2 antibodies, several approaches are recommended:

• Positive control selection: Use cell lines known to express CHST2, such as MOLT-4 human acute lymphoblastic leukemia cells or Jurkat human acute T cell leukemia cells, which have demonstrated detectable CHST2 expression by Western blot .

• Band verification: In Western blot applications, verify that the detected band appears at the expected molecular weight of approximately 50-52 kDa under reducing conditions .

• Knockout/knockdown validation: Compare antibody signals between wildtype cells and cells with CHST2 knockdown or knockout to confirm specificity .

• Multiple detection methods: Confirm CHST2 expression using alternative methods such as qPCR for mRNA levels in parallel with protein detection .

What are the optimal conditions for Western blot detection of CHST2?

For optimal Western blot detection of CHST2, the following protocol elements should be considered:

• Sample preparation: Prepare lysates from appropriate cell lines such as MOLT-4 or Jurkat cells under reducing conditions .

• Gel selection: Use a 7.5% SDS-PAGE gel for effective separation .

• Membrane choice: PVDF membranes have been successfully used for CHST2 detection .

• Antibody concentration: Use primary CHST2 antibody at approximately 1 μg/mL concentration or at dilutions between 1:500-1:3000 depending on the specific antibody .

• Detection system: After primary antibody incubation, use an appropriate HRP-conjugated secondary antibody specific to the host species of the primary antibody (e.g., Anti-Goat IgG for goat primary antibodies) .

• Buffer selection: Immunoblot Buffer Group 8 has been reported as effective for CHST2 detection .

Following this protocol should allow visualization of CHST2 as a specific band at approximately 50-52 kDa .

How can I effectively use CHST2 antibodies for immunocytochemistry/immunofluorescence studies?

For optimal ICC/IF detection of CHST2, researchers should follow these methodological guidelines:

• Cell fixation: Methanol fixation has been documented as effective for CHST2 antibody applications in ICC/IF .

• Antibody dilution: Use CHST2 primary antibodies at dilutions between 1:100-1:1000, with 1:500 being an effective starting point for optimization .

• Cell line selection: Cell lines such as MCF-7 have been successfully used for CHST2 detection using ICC/IF methods .

• Visualization: Use fluorophore-conjugated secondary antibodies specific to the host species of the primary antibody for detection.

• Controls: Include negative controls (omitting primary antibody) and positive controls (cells known to express CHST2) in each experiment to validate specific staining.

The expected localization pattern should be consistent with CHST2's known subcellular distribution in the Golgi apparatus, though expression patterns may vary depending on the cell type and experimental conditions .

How can CHST2 antibodies be used to investigate cancer metastasis mechanisms?

Recent research has established CHST2's role in cancer progression, particularly in breast cancer metastasis . Researchers can leverage CHST2 antibodies to investigate these mechanisms through the following approaches:

• Expression correlation studies: Use CHST2 antibodies in Western blot or IHC to correlate CHST2 expression levels with metastatic potential across cancer cell lines or patient samples .

• Functional analysis in metastasis models: Combine CHST2 antibody-based detection with in vivo metastasis models, such as tail-vein injection of luciferase-labeled breast cancer cells with modulated CHST2 expression levels .

• MECA79 antigen interaction: Investigate the relationship between CHST2 expression and MECA79 antigen synthesis using dual detection methods with appropriate antibodies .

• Pathway analysis: Use CHST2 antibodies alongside other markers to investigate the Snail-CHST2-MECA79 axis in cancer progression, which has been implicated in breast cancer metastasis .

Research has shown that CHST2 depletion inhibits breast cancer cell migration and metastasis, while overexpression promotes these processes, making CHST2 a potential therapeutic target .

What approaches can be used to investigate the sulfotransferase activity of CHST2 in experimental systems?

Investigating the enzymatic activity of CHST2 requires specialized approaches beyond standard antibody applications:

• Sulfation inhibitor studies: Combine CHST2 antibody detection with sulfation inhibitors such as sodium chlorate to correlate CHST2 expression with sulfation activity .

• Functional mutant analysis: Use antibodies to detect both wild-type CHST2 and enzymatically inactive mutants (e.g., CHST2-N475A) to correlate protein expression with sulfotransferase function .

• Substrate detection: Use antibodies against known CHST2 substrates or modified epitopes, such as MECA79 antigen, to assess CHST2 activity indirectly .

• Flow cytometry applications: Employ flow cytometric analysis to quantify cell surface MECA79 antigen expression as a readout of CHST2 activity in various experimental conditions .

Research has demonstrated that CHST2-mediated sulfation of MECA79 antigens plays a critical role in breast cancer cell migration, which can be inhibited by blocking with specific antibodies against MECA79 or by treatment with the sulfation inhibitor sodium chlorate .

How can I design experiments to investigate the relationship between Snail transcription factor and CHST2 expression?

Studies have identified CHST2 as a Snail-induced gene in breast cancer cells . To investigate this relationship:

• ChIP assays: Use chromatin immunoprecipitation with Snail antibodies to detect direct binding to the CHST2 promoter region, as demonstrated in MDA-MB-231 cells and MCF-10A-Snail cells .

• Promoter activity assays: Employ luciferase reporter assays with wild-type and mutant CHST2 promoter constructs to assess Snail-mediated activation .

• Expression correlation analysis: Use Western blot or qPCR to analyze CHST2 expression levels in response to Snail overexpression or knockdown .

• Functional rescue experiments: In Snail-overexpressing cells, knockdown CHST2 and assess whether this rescues the phenotypic effects of Snail overexpression .

Research has shown that Snail binds directly to the CHST2 promoter through two putative binding sites, and mutation of these sites abolishes Snail-mediated activation of CHST2 transcription .

What are the common challenges in CHST2 antibody applications and how can they be addressed?

Researchers may encounter several challenges when working with CHST2 antibodies:

• High background: This can be addressed by:

  • Increasing blocking time or concentration

  • Using different blocking agents (BSA, normal serum, commercial blockers)

  • Optimizing antibody dilutions

  • Increasing washing stringency and duration

• Weak or no signal: To improve signal detection:

  • Verify CHST2 expression in your cell line

  • Use positive control samples known to express CHST2 (MOLT-4, Jurkat cells)

  • Optimize protein loading amounts

  • Consider alternative antibody clones or detection systems

• Non-specific bands: To enhance specificity:

  • Optimize antibody concentration

  • Ensure appropriate blocking

  • Use gradient gels for better separation

  • Consider more stringent washing conditions

• Inconsistent results: For improved reproducibility:

  • Standardize lysate preparation protocols

  • Maintain consistent experimental conditions

  • Use internal loading controls

  • Document all experimental parameters

How should researchers interpret CHST2 detection results in the context of cancer research?

When interpreting CHST2 expression data in cancer research:

• Expression level context: Consider CHST2 expression in the context of known cancer progression markers, particularly Snail expression which has been shown to induce CHST2 .

• Functional correlation: Correlate CHST2 expression levels with functional outcomes such as cell migration ability, metastatic potential, or MECA79 antigen expression .

• Subcellular localization: Consider the subcellular localization of CHST2, which should be primarily in the Golgi apparatus as it is a Golgi-localized type II membrane protein .

• Molecular weight variations: Be aware that post-translational modifications may cause slight variations in the observed molecular weight of CHST2, which typically appears at approximately 50-52 kDa .

• Pathway integration: Interpret CHST2 data within the broader context of the Snail-CHST2-MECA79 axis and related cancer progression pathways .

Research has demonstrated that CHST2 depletion inhibits breast cancer cell migration and metastasis, while overexpression promotes these processes, making CHST2 expression levels potentially relevant to cancer prognosis and therapeutic approaches .

How might CHST2 antibodies be utilized in developing novel cancer therapeutic approaches?

As CHST2 has been implicated in cancer progression, particularly breast cancer metastasis, CHST2 antibodies could contribute to therapeutic development in several ways:

• Target validation: Use CHST2 antibodies to validate this enzyme as a therapeutic target by confirming its expression and activity in various cancer types and correlating with clinical outcomes .

• Therapeutic development: Develop therapeutic antibodies or small molecules targeting CHST2 activity, which could be validated using existing CHST2 antibodies for mechanism-of-action studies .

• Companion diagnostics: Utilize CHST2 antibodies in developing diagnostic assays to identify patients who might benefit from CHST2-targeted therapies .

• Combination therapy assessment: Use CHST2 antibodies to study the effects of combining CHST2 inhibition with other cancer therapies, such as those targeting the Snail transcription factor or downstream pathways .

Research has shown that blocking the MECA79 antigen with specific antibodies can override cell migration mediated by CHST2, suggesting that targeting the CHST2-MECA79 axis could be a viable therapeutic approach for inhibiting breast cancer metastasis .

What are the current knowledge gaps in CHST2 research that could benefit from improved antibody-based detection methods?

Several knowledge gaps in CHST2 biology could be addressed with improved antibody-based detection:

• Tissue-specific expression patterns: Development of highly specific antibodies suitable for immunohistochemistry could help map CHST2 expression across different tissues and cancer types beyond breast cancer .

• Regulatory mechanisms: Improved antibodies for chromatin immunoprecipitation and protein interaction studies could help elucidate additional transcriptional and post-translational regulators of CHST2 beyond Snail .

• Substrate specificity: Development of antibodies recognizing CHST2-specific sulfation patterns could help identify the full range of CHST2 substrates beyond the known MECA79 antigens .

• Isoform-specific functions: Antibodies capable of distinguishing between potential CHST2 isoforms could help determine whether different forms have distinct functions in normal physiology and disease .

• Prognostic value: Standardized antibody-based assays for CHST2 detection in clinical samples could help determine its value as a prognostic or predictive biomarker in various cancer types .

Addressing these knowledge gaps could significantly advance our understanding of CHST2 biology and its potential as a therapeutic target in cancer and other diseases.